This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.
A phase III study showed that APF530 could improve control of emesis in cancer patients receiving highly emetogenic chemotherapy.
A large database study found that the use of neoadjuvant chemotherapy in breast cancer patients does not raise the risk of postoperative surgical complications.